Hongene Biotechnology

What Hongene Biotechnology does

Hongene Biotech Corporation is a privately-held, vertically-integrated contract development and manufacturing organization (CDMO) specializing in nucleic acid manufacturing, founded in 1998 and headquartered with operations in Shanghai (China), Union City (USA), Hamburg (Germany), and Tokyo (Japan). The company converts nearly three decades of RNA-focused expertise into a single-source platform that spans raw materials — phosphoramidites, GalNAc conjugates, linkers, nucleoside triphosphates, cap analogs, enzymes, and other reagents across more than 2,000 SKUs — through to GMP-grade oligonucleotide and mRNA drug product. Service offerings are organized around three CDMO lines (oligonucleotide, mRNA, and custom synthesis), and the company also distributes standardized reagents direct-to-customer through an e-commerce storefront (shop.hongene.com).

The underlying technology platform combines oligonucleotide synthesis, mRNA synthesis, and lipid nanoparticle (LNP) delivery capabilities, augmented by an inbound license for exNA oligonucleotide technology from UMass Chan Medical School. Hongene addresses pharmaceutical and biotechnology customers developing antisense oligonucleotides, siRNA, mRNA vaccines, gene editing components, and diagnostic reagents, with additional reach into global health initiatives via a Bill & Melinda Gates Foundation grant to develop patent-free cap analogs for mRNA vaccines targeting low- and middle-income countries.

Hongene operates a B2B revenue model combining enterprise CDMO project engagements with a hardware-like raw materials and reagents catalog. Customers are reached through direct field sales for CDMO contracts (accompanied by regulatory support) and self-service online ordering for catalog products. Pricing is quote-based and not publicly disclosed. Strategic posture is supported by a stacked partnership cadence across ReciBioPharm (gene editing CDMO), UMass Chan (exNA licensing), the Gates Foundation (cap analogs for global health), and SiranBio (CDMO support for chronic hepatitis B siRNA), positioning the company within the USD 17.42 billion (2025) nucleic acid therapeutics CDMO market and the USD 2.22 billion (2025) mRNA synthesis raw materials market, both projected to grow at roughly 14% CAGR through the next decade.

Name

Hongene Biotechnology

Legal name

Hongene Biotech Corporation

Website

https://hongene.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Short description

Hongene Biotech Corporation is a vertically-integrated CDMO manufacturing nucleic acid raw materials (2,000+ SKUs) and providing oligonucleotide, mRNA, and custom synthesis CDMO services to pharmaceutical and biotech companies developing RNA-based therapeutics globally.

Ownership category

akta.pro rank

Product category

Nucleic Acid CDMO & Raw Materials Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• Nucleic acid manufacturing
• Oligonucleotide CDMO
• MRNA synthesis reagents
• Phosphoramidite raw materials
• GMP drug product manufacturing

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization (CDMO) services providing integrated oligonucleotide and mRNA manufacturing from raw materials to GMP drug product for biotech and pharma clients
2. Technology Licensing: Licensing of proprietary technologies including exNA oligonucleotide technology to other manufacturers and research institutions
3. Raw Materials and Reagents Sales: Sale of raw materials including phosphoramidites, nucleotides, cap analogs, enzymes, and other reagents for oligonucleotide and mRNA synthesis, supporting both research and commercial scale manufacturing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Hongene Biotech Corporation manufactures nucleic acid raw materials (phosphoramidites, cap analogs, nucleotides, enzymes, GalNAc conjugates, linkers) and provides contract development and manufacturing organization (CDMO) services for oligonucleotide and mRNA therapeutics. The platform is vertically integrated from raw materials to GMP drug product, serving pharmaceutical and biotechnology customers with a portfolio of more than 2,000 SKUs. End-to-end engagement covers antisense oligonucleotides, siRNA, mRNA vaccines, and gene editing therapies, with global manufacturing presence in the USA, Germany, Japan, and China.

Product overview

Hongene Biotech Corporation operates as a vertically-integrated CDMO (Contract Development and Manufacturing Organization) specializing in nucleic acid manufacturing with a portfolio of over 2,000 SKUs. The company offers a comprehensive product portfolio spanning raw materials for oligonucleotide and mRNA synthesis (including Phosphoramidites, PMO, PNA, GalNAc Conjugates, Cap Analogs, Nucleotides, and Enzymes), diagnostic reagents, and finished mRNA products. These raw materials feed into three main service offerings: Oligonucleotide CDMO Services, mRNA CDMO Services, and Custom Synthesis Services, enabling end-to-end support from raw material supply through GMP drug product manufacturing for RNA-based therapeutics and vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• Phosphoramidites Phosphoramidite building blocks used in oligonucleotide synthesis, forming the phosphodiester backbone of DNA and RNA sequences for research and therapeutic applications.
• PMO (Phosphorodiamidate Morpholino Oligomers) Synthetic oligonucleotide analogs with a morpholino ring structure, used in antisense therapy applications requiring enhanced stability and binding affinity.
• PNA (Peptide Nucleic Acids) Synthetic DNA analogs with a peptide backbone, offering high thermal stability and resistance to nucleases and proteases for diagnostic and therapeutic applications.
• Succinates Succinylated nucleoside derivatives used as protecting groups in oligonucleotide synthesis workflows.
• Dyes & Quenchers Fluorescent dyes and quenchers for oligonucleotide labeling used in diagnostics, qPCR, and fluorescence-based detection assays.
• GalNAc Conjugates N-acetylgalactosamine conjugates enabling targeted delivery of oligonucleotides to hepatocytes via asialoglycoprotein receptor-mediated uptake for liver-targeted therapeutics.
• Solid Support Solid-phase synthesis supports used as the foundation for oligonucleotide synthesis on automated synthesizers.
• Oligo Reagents Auxiliary reagents and chemicals required for oligonucleotide synthesis processes.
• Enzymes & Related Buffer for mRNA Enzymes and optimized buffers for mRNA synthesis, including capping enzymes and processing components for in vitro transcription workflows.
• Nucleotides for mRNA Nucleotide triphosphates and modified nucleotides used as building blocks in mRNA synthesis, including modified bases for enhanced stability and reduced immunogenicity.
• Stock mRNA Pre-synthesized mRNA products available for research and development use.
• Cap Analogs mRNA capping analogs, including natural and modified cap structures, for enhancing translation efficiency and stability of mRNA therapeutics.
• Kits for mRNA Complete kit solutions for mRNA synthesis, containing all necessary components for in vitro transcription and processing.
• LNP Devices Lipid nanoparticle formulation devices for mRNA delivery system development.
• Nucleotides for Diagnostics Nucleotide reagents specifically formulated for diagnostic applications including qPCR and next-generation sequencing.
• Phosphoramidites for Diagnostics Diagnostic-grade phosphoramidite building blocks meeting purity requirements for clinical and research diagnostic assays.
• Dyes & Quenchers for Diagnostics Diagnostic-specific fluorescent dyes and quenchers for molecular diagnostics and point-of-care testing applications.
• Kits for Diagnostics Diagnostic kit solutions for nucleic acid testing and molecular diagnostics.
• Nucleosides Natural and modified nucleosides serving as fundamental building blocks for oligonucleotide and nucleoside analog synthesis.
• Protected Nucleosides (PNS) Protection-group-modified nucleosides required for selective activation and controlled synthesis in oligonucleotide manufacturing.
• Nucleotides Natural and modified nucleotides, including nucleoside mono-, di-, and triphosphates, for various nucleic acid applications.
• Dyes & Quenchers Precursor Precursor compounds for fluorescent dye and quencher synthesis, used in labeled oligonucleotide production.
• Linkers Bifunctional linker molecules for conjugating oligonucleotides to targeting moieties, labels, or surfaces.
• Sugars Sugar derivatives including ribose and deoxyribose analogs used in nucleoside and nucleotide analog synthesis.
• Reagents General chemical reagents used in nucleic acid synthesis and processing workflows.
• Oligonucleotide CDMO Services Contract development and manufacturing organization services for oligonucleotide therapeutics, providing integrated support from raw materials through GMP drug product.
• mRNA CDMO Services End-to-end mRNA therapeutic development and manufacturing services including synthesis, capping, purification, and formulation.
• Custom Synthesis Services Bespoke synthesis services for custom oligonucleotides, modified nucleic acids, and specialized nucleoside analogs meeting specific research or manufacturing requirements.

Quantifiable outcome

• Global nucleic acid therapeutics CDMO market growing at 14.18% CAGR from USD 17.42 billion (2025) to USD 57.37 billion (2034)
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• SiranBiocoreStrategic or Co-development Partner · 19 May 2026CDMO support for SiranBio's SA1211 program, a dual-target siRNA candidate for chronic hepatitis B. Hongene provided integrated services across multiple stages from raw materials to regulatory support, demonstrating capabilities for complex oligonucleotide therapeutics.
• UMass Chan Medical SchoolcoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Licensing deal for exNA oligonucleotide technology, with Hongene supplying the technology to the market under the licensing agreement. This extends Hongene's advanced oligonucleotide capabilities through inbound IP licensing.
• ReciBioPharmcoreStrategic or Co-development Partner · 19 November 2024Partnership to provide end-to-end gene editing CDMO services, integrating sgRNA production at ReciBioPharm's facility. The collaboration aims to streamline the development and manufacturing process for gene editing therapies by reducing supply chain complexity for developers.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• GenScript: GenScript offers gene synthesis, oligonucleotide manufacturing, and CDMO services including mRNA and gene therapy — overlapping with Hongene's raw materials, custom synthesis, and nucleic acid CDMO capabilities.
• Nitto Denko Avecia: Avecia is a dedicated oligonucleotide CDMO offering development and GMP manufacturing for antisense and siRNA therapeutics — directly comparable to Hongene's oligonucleotide CDMO service line.
• TriLink BioTechnologies (Maravai LifeSciences): TriLink is a specialist in mRNA raw materials (cap analogs, NTPs, CleanCap) and CDMO services, making it one of the closest direct peers to Hongene's mRNA raw materials and mRNA CDMO business.
• LGC Biosearch Technologies: LGC Biosearch Technologies manufactures oligonucleotides, probes, and qPCR/diagnostic reagents — overlapping with Hongene's raw materials catalog and diagnostic reagent product lines.
• Aldevron (Danaher): Aldevron, now part of Danaher, is a leading nucleic acid CDMO providing plasmid DNA, mRNA, and recombinant protein services — directly comparable to Hongene's CDMO offerings in mRNA and gene editing support.
• Eurofins Genomics: Eurofins Genomics provides custom oligonucleotide synthesis and nucleic acid services at scale across multiple continents, comparable to Hongene's catalog and custom synthesis offerings for research and commercial customers.
• Wuxi AppTec (STA Pharmaceutical): Wuxi STA is the largest China-based oligonucleotide and small-molecule CDMO and the most direct competitor to Hongene in nucleic acid contract manufacturing, offering overlapping oligonucleotide and mRNA CDMO services to global biotech.
• Asymchem Laboratories: Asymchem is a China-headquartered CDMO expanding into oligonucleotide and nucleic acid manufacturing; it competes with Hongene particularly in serving Asian and global biotech CDMO needs.
• BioSpring: BioSpring is a Germany-based oligonucleotide CDMO with vertically integrated capabilities across raw materials through API, directly competing with Hongene for European oligonucleotide manufacturing customers.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher operates a massive life sciences services and CDMO business (Patheon) that includes nucleic acid and oligonucleotide offerings as part of a broad portfolio — a broad incumbent against which Hongene's focused nucleic acid platform competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hongene-biotech-corporation-usa

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hongene Biotechnology